Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances
NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT
NANALYSIS ANNOUNCES UP TO $5.0 MILLION BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND UP TO $1.0 MILLION CONCURRENT PRIVATE PLACEMENT
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
